HLB PEP and HLB Science Partner to Develop Antimicrobial and Antiviral Peptides

(From left) HLB PEP Co-CEOs Shim Kyung-jae and Kim Jae-il, and HLB Science CEO Yoon Jong-sun pose for a photo during the signing ceremony for the joint development of antimicrobial and antiviral peptide therapeutics. (Photo courtesy of HLB Group)

 

HLB PEP and HLB Science, two biotech affiliates of HLB Group, have signed a joint development agreement to co-develop next-generation peptide-based antimicrobial and antiviral therapeutics. The partnership focuses on advancing treatments for multidrug-resistant bacteria and viral infections, with lead candidates AGM-290 and AGM-380 targeting bacterial membranes and viral proteins. The collaboration leverages HLB PEP’s proprietary drug pipeline and HLB Science’s clinical expertise to fast-track global trials and commercialization, forming part of HLB Group’s strategic internal bio ecosystem initiative.

Read more: https://www.ittimes.com/news/articleView.html?idxno=79784

HLB PEP and HLB Science Partner to Develop Antimicrobial and Antiviral Peptides - IT타임스